INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Turin
Turín, ItaliaPublicaciones en colaboración con investigadores/as de University of Turin (156)
2024
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection
-
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Hematological Oncology, Vol. 42, Núm. 1
2023
-
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
International Journal of Infectious Diseases, Vol. 137, pp. 98-110
-
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
Leukemia, Vol. 37, Núm. 2, pp. 388-395
-
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
Frontiers in Oncology, Vol. 13
-
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529
-
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Gut, Vol. 72, Núm. 6, pp. 1054-1072
-
European Society of Thoracic Surgeons expert consensus recommendations on technical standards of segmentectomy for primary lung cancer
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 63, Núm. 6
-
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Blood
-
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
Molecular cancer, Vol. 22, Núm. 1, pp. 119
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study
Hematological Oncology
-
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood cancer journal, Vol. 13, Núm. 1, pp. 116
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
-
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone
Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536
-
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 15, pp. 2827-2842
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
-
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
The Lancet Haematology, Vol. 10, Núm. 10, pp. e813-e824
2022
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology